EGFR activation limits the response of liver most cancers to lenvatinib

0
22

  • 1.

    Villanueva, A. Hepatocellular Carcinoma. N. Engl. J. Med. 380, 1450-1462 (2019).

    CAS article Google Scholar

  • 2.

    Kudo, M. et al. Lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma: a phase 3 randomized non-inferiority study. Lancet 391, 1163-1173 (2018).

    CAS article Google Scholar

  • 3.

    Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of the incidence and mortality worldwide for 36 cancers in 185 countries. CA Krebs J. Clin. 71: 209-249 (2021).

    Article Google Scholar

  • 4th

    Zucman-Rossi, J., Villanueva, A., Nault, J.-C. & Llovet, JM Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149, 1226-1239 (2015).

    CAS article Google Scholar

  • 5.

    Llovet, JM et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).

    CAS article Google Scholar

  • 6th

    Finn, RS et al. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, ​​1894-1905 (2020).

    CAS article Google Scholar

  • 7th

    Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechn. 34, 631-633 (2016).

    CAS article Google Scholar

  • 8th.

    Zhu, AX et al. SEARCH: a randomized, double-blind, placebo-controlled phase III study of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33: 559-566 (2015).

    CAS article Google Scholar

  • 9.

    Matsuki, M. et al. Lenvatinib inhibits angiogenesis and signaling pathways of tumor fibroblast growth factor in human hepatocellular carcinoma models. Krebs Med. 7, 2641-2653 (2018).

    CAS article Google Scholar

  • 10.

    Wagle, M.-C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in several cancers. NPJ Exactly. Oncol. 2, 7 (2018).

    Article Google Scholar

  • 11.

    Pirker, R. et al. EGFR expression as a predictor of survival with first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13: 33-42 (2012).

    CAS article Google Scholar

  • 12th

    Kimura, T. et al. The immunomodulatory activity of lenvatinib contributes to the antitumor activity in the hepatocellular carcinoma model Hepa1-6. Cancer Sci. 109, 3993-4002 (2018).

    CAS article Google Scholar

  • 13th

    Li, E., Lin, L., Chen, CW & Ou, DL Mouse models for immunotherapy in hepatocellular carcinoma. Cancer Diseases (Basel) 11, 1800 (2019).

    CAS article Google Scholar

  • 14th

    Keng, VW et al. A conditional transposon-based insertion mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechn. 27: 264-274 (2009).

    CAS article Google Scholar

  • fifteen.

    Er, H. et al. The platelet-derived growth factor requires an epidermal growth factor receptor to activate the kinases of the p21-activated kinase family. J. Biol. Chem. 276: 26741-26744 (2001).

    CAS article Google Scholar

  • 16.

    Lee, S.-W. et al. The EGFR-Pak signaling pathway selectively regulates macropinocytosis induced by glutamine deficiency. Dev. Cell 50: 381-392 (2019).

    CAS article Google Scholar

  • 17th

    Vaseva, AV et al. The breakdown of MYC induced by KRAS suppression is antagonized by a MEK5-ERK5 compensation mechanism. Krebszelle 34, 807-822 (2018).

    CAS article Google Scholar

  • 18th

    Duncan, JS et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple negative breast cancer. Cell 149: 307-321 (2012).

    CAS article Google Scholar

  • 19th

    Lito, P. et al. The alleviation of the profound feedback inhibition of mitogenic signaling by RAF inhibitors weakens their activity in BRAFV600E melanoma. Krebszelle 22, 668-682 (2012).

    CAS article Google Scholar

  • 20th

    Kosoff, RE et al. Pak2 inhibits endomitosis during megakaryopoiesis and changes the organization of the cytoskeleton. Blood 125, 2995-3005 (2015).

    CAS article Google Scholar

  • 21.

    Kobayashi, S. et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of the signal transduction of the mutated epidermal growth factor receptor. Krebs Res. 66, 11389-11398 (2006).

    CAS article Google Scholar

  • 22nd

    Philip, PA et al. Phase II trial of erlotinib (OSI-774) in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 23: 6657-6663 (2005).

    CAS article Google Scholar

  • 23

    Chan, SL et al. New use of an old marker: serial α-fetoprotein measurement to predict radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 27: 446-452 (2009).

    CAS article Google Scholar

  • 24.

    Llovet, JM & Lencioni, R. mRECIST for HCC: Performance and New Refinements. J. Hepatol. 72, 288-306 (2020).

    Article Google Scholar

  • 25th

    Ding, X. et al. Genomic and epigenomic characteristics of primary and recurrent hepatocellular carcinomas. Gastroenterology 157, 1630-1645 (2019).

    CAS article Google Scholar

  • 26th

    Cremolini, C. et al. Early tumor shrinkage and response depth predict the long-term outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab: results of the Phase III TRIBE study by the Gruppo Oncologico del Nord Ovest. Ann. Oncol. 26: 1188-1194 (2015).

    CAS article Google Scholar

  • 27

    Love, MI, Huber, W. & Anders, S. Moderated Estimation of Folding Change and Dispersion for RNA-seq Data Using DESeq2. Genom Biol. 15, 550 (2014).

    Article Google Scholar

  • 28.

    Jin, H. et al. Regulator of the calcineurin-1 gene isoform 4, which is downregulated in hepatocellular carcinoma, prevents the proliferation, migration and invasive activity of cancer cells and the metastasis of orthotopic tumors by inhibiting the nuclear translocation of NFAT1. Gastroenterology 153, 799-811 (2017).

    CAS article Google Scholar

  • 29

    Mazières, J. et al. Assessment of EGFR Protein Expression by Immunohistochemistry Using the H-Score and the Magnification Rule: Re-Analysis of the SATURN Study. Lung Cancer 82, 231-237 (2013).

    Article Google Scholar

  • 30th

    Sun, C. et al. Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma. Nature 508, 118-122 (2014).

    ADS CAS Article Google Scholar

  • 31.

    Wang, L. et al. High-throughput screenings with functional genes and compounds identify targets for senescence induction in cancer. Cell Rep. 21, 773-783 (2017).

    CAS article Google Scholar

  • 32.

    Schuhmacher, M. et al. The human B-cell line transcription program in response to Myc. Nucleic Acids Res. 29, 397-406 (2001).

    CAS article Google Scholar

  • 33.

    Wang, C. et al. Inducing and exploiting weak points for the treatment of liver cancer. Nature 574, 268-272 (2019).

    ADS CAS Article Google Scholar

  • 34.

    World Medical Association. Declaration of the World Medical Association of Helsinki. Ethical principles for medical research on humans. Bull. World Health Organ. 79: 373-374 (2001).

    PubMed Central Google Scholar

  • LEAVE A REPLY

    Please enter your comment!
    Please enter your name here